Provided herein are methods for identifying compounds that are inhibitors of a calcium-activated chloride channel. Aminothiophene and aminothiazole compounds, and compositions comprising these compounds, described herein that inhibit efflux of chloride through a calcium-activated chloride channel are useful for treating diseases, disorders, and sequelae of diseases, disorders, and conditions that are associated with aberrantly increased chloride and fluid secretion, for example, secretory diarrhea.

The present invention relates to novel light-emitting materials. These materials comprise a side chain that includes a fully deuterated or partially deuterated alkyl chain. This new side chain could improve device lifetime compared to nondeuterated side chains.

The present invention relates to novel light-emitting materials. These materials comprise a side chain that includes a fully deuterated or partially deuterated alkyl chain. This new side chain could improve device lifetime compared to nondeuterated side chains.

A fused fluoranthene compound which includes an indeno[3,2-b]fluoranthene skeleton having a hetero atom is a novel compound, which is useful as a material for organic electroluminescence devices for use in an organic electroluminescence device and an electronic equipment.

A fused fluoranthene compound which includes an indeno[3,2-b]fluoranthene skeleton having a hetero atom is a novel compound, which is useful as a material for organic electroluminescence devices for use in an organic electroluminescence device and an electronic equipment.

A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder:

##STR00001## (meanings of the symbols that are included in the formula are as given in the specification).

A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder:

##STR00001## (meanings of the symbols that are included in the formula are as given in the specification).

Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

A compound represented by formula (1):

##STR00001##

wherein Ar is a substituted or unsubstituted alkyl group having 1 to 20 carbon atoms, a substituted or unsubstituted aryl group having 6 to 30 ring carbon atoms, or a substituted or unsubstituted nitrogen-comprising heteroaryl group having 5 to 30 ring atoms; each of L.sub.1 and L.sub.2 is independently a single bond, a substituted or unsubstituted arylene group having 6 to 30 ring carbon atoms, a substituted or unsubstituted heteroarylene group having 5 to 30 ring atoms, or a substituted or unsubstituted divalent linking group wherein 2 to 4 groups selected from an arylene group having 6 to 30 ring carbon atoms and a heteroarylene group having 5 to 30 ring atoms are bonded to each other via a single bond; A is a monovalent group represented by formula (2); and B is a monovalent group represented by formula (5):

##STR00002##

wherein R.sub.1 to R.sub.10 and R.sub.21 to R.sub.30 are as defined in the description, enables the emission of light of a purer blue (shorter wavelength), a narrower half width (higher color purity), and a single peak with no second peak.